Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 33,170 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Catheter-Related Fungal Infections
Interventions: Micafungin lock therapy; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 6 Months to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acne Vulgaris
Interventions: DMT310, Placebo; Drug
Lead sponsor: Dermata Therapeutics; Industry
Eligibility: 9 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Freemont, California • Austin, Texas

Conditions: Ulcerative Colitis
Interventions: SER-287, Placebo, Placebo Pre-Treat, Vancomycin Pre-Treat; Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Marlborough, Massachusetts

Conditions: Alcohol Drinking, Anxiety Disorders
Interventions: Anxiety Attention Training, Alcohol Attention Training, Control Training; Behavioral
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Anorexia, Cachexia, Weight Loss
Interventions: Megestrol acetate concentrated suspension 110 mg/mL, Megestrol acetate concentrated suspension 60 mg/mL, Placebo; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 4
States / cities: Anaheim, California • Flat Rock, North Carolina • High Point, North Carolina + 1 more

Conditions: Healthy
Interventions: Sodium ST20; Drug
Lead sponsor: HemaQuest Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Food Allergy
Interventions: Chinese Herbal Medication, Placebo, Omalizumab, Multi OIT; Drug
Lead sponsor: Xiu-Min Li; Other
Eligibility: 6 Years to 40 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Community-acquired Pneumonia, Cognition Disorder
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions: Benralizumab Arm A, Benralizumab Arm B, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 138
States / cities: Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 114 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sleep Disorders, Congestion, Nasal
Interventions: Prototype Nasal Dilator, Marketed Nasal Strip, Placebo Nasal Strip; Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Paramus, New Jersey • Bethlehem, Pennsylvania

Conditions: Spondylitis, Ankylosing
Interventions: Secukinumab, Placebo secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 14
States / cities: Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 11 more

Conditions: Intestinal Multi-drug Resistant Organism Colonization
Interventions: Microbiome Therapeutic, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Tympanic Membrane Perforation
Interventions: FGF-2, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Nicotine Dependence, Smoking Cessation
Interventions: Nicotrol Inhaler, Placebo Inhaler; Drug
Lead sponsor: UConn Health; Other
Eligibility: 16 Years and older · Female only
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Hartford, Connecticut • Springfield, Massachusetts

Conditions: Metabolic Syndrome, Morbid Obesity, Hypercholesterolemia, Hyperglycemia
Interventions: Tetrahydrocannabivarin, Placebo; Drug · Other
Lead sponsor: Medical Life Care Planners, LLC; Other
Eligibility: 18 Years to 100 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Lymphoma
Interventions: Pegfilgrastim, Loratadine, Placebo, Questionnaires; Drug · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Interventions: Glasdegib (PF-04449913), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 6 more

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Ocrelizumab; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Vocal Cord Disease, Vocal Cord Polyp, Vocal Cord Cyst
Interventions: Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension), Superior laryngeal nerve block - Placebo (saline); Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Alcohol Dependence
Interventions: Placebo, Naltrexone, Naltrexone + Aripiprazole; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Glycopyrronium bromide, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 33
States / cities: Birmingham, Alabama • Fairhope, Alabama • Glendale, Arizona + 30 more

Conditions: Friedreich's Ataxia
Interventions: RT001, Placebo; Drug
Lead sponsor: Biojiva LLC; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Long Beach, California • Los Angeles, California • Gainesville, Florida + 3 more

Conditions: Cognitive Dysfunction
Interventions: iomazenil; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: West Haven, Connecticut

Search by objective public record fields.

Micafungin Lock Therapy

DMT310-009 Topical in the Treatment of Acne Vulgaris

A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis

Retraining Attention to Treat Alcohol Dependence and Social Anxiety

Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension

A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers

E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy

Corticosteroids in Community Acquired Pneumonia

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)

Exploratory Subjective Sleep Study of a Prototype Nasal Dilator

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

Further MT for Antibiotic-Resistant Bacterial Colonization

Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations

Nicotine Replacement for Smoking Cessation During Pregnancy

Weight Loss, Blood Sugar and Blood Lipid Effects of Tetrahydrocannabivarin (THCV) Impregnated Mucoadhesive Strips

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)

Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery

An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence

A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

GABA-glutamate Interactions and Psychosis